Authors
Latest:
The urologist in the world of precision medicine"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.
Latest:
The status and future direction of advanced urine testing: multiplex PCR"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.
Latest:
Genomic and imaging advances drive precision medicine progress in prostate cancerRohan Garje, MD, discusses precision medicine in metastatic prostate cancer, including genomic testing, targeted therapies, and theragnostics.
Latest:
Darolutamide safety in nmCRPC sustained with prolonged exposureSafety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.
Latest:
Study assesses impact of health literacy on chronic pelvic painAddressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.
Latest:
Automated medical coding benefits both the practice and the patientsWhen you add automation, your medical coding not only improves your margins but also plays a key role in improving patient care.
Latest:
Multidisciplinary Care for Patients With mCRPCIn the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.
Latest:
What the SWIU Census reveals about the state of women in urology"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.
Latest:
Urologic research and COVID-19: Unmasking the silver liningIn this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
Latest:
Treatment at high-volume facilities linked to improved survival in node-positive prostate cancerThe improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.
Latest:
“Shooting for the Moon” means reducing metastatic prostate cancer diagnoses“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.
Latest:
Clinical Pearls and Future of Bladder Cancer TreatmentEric A. Singer, MD, MA, FACS, looks to the future of bladder cancer treatment and offers advice for community urologists and urologic oncologists treating patients with the disease.
Latest:
Urologic implications of Lynch syndromeResearch indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.
Latest:
Is video-based research feasible for pediatric urology visits?"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.
Latest:
Considerations for palliative care in urologic oncologyBenefits include improved quality of life and symptom management.
Latest:
United Urology Group and its affiliate practices and Prostate Centers USA® are collaborating to revolutionize men's health care with minimally invasive solutionsThe inclusion of PAE in the American Urological Association BPH Guidelines offers a non-surgical alternative that can provide long-term relief with minimal downtime and fewer complications, according to the United Urology Group.
Latest:
Triplet therapy including darolutamide should be standard of care in mCSPC, data indicateResults of the ARASENS trial (NCT02799602) demonstrated that darolutamide plus ADT and docetaxel prolonged overall survival regardless of disease volume or risk.
Latest:
Real-world data point to underutilization of germline, somatic testing in mCRPC"Certainly germline and somatic is recommended for all mCRPC patients to detect HR gene mutations, and consider options for PARP inhibitors,” says Neal Shore, MD, FACS.
Latest:
Chronic orchialgia: How to diagnose and treat the challenging conditionIn this interview, Parviz K. Kavoussi, MD, discusses his diagnostic work-up for patients who present with chronic testicular pain and describes conservative and surgical management approaches for the condition.
Latest:
Expert explains why automation is key to prior authorization reformAutomating prior authorization is an investment that every health care organization should consider. As the industry grapples with rapid regulatory shifts and acute staff shortages, a tailored automation strategy is key to enhancing patient care and improving operational efficiency.
Latest:
How data and technology facilitate health equity and boost the overall patient experience"Digital engagement technology, which can be seamlessly integrated into a health system or hospital's existing processes," writes Chelsea King Arthur.
Latest:
Enhancing Patient-Centric Management in OAB in 2024 and BeyondPanelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.
Latest:
Vikram Narayan, MD, on the use of augmented reality to assist in resident training“Put another way, with Apple Vision Pro, what we're hoping to do is have our residents be able to put on a headset and walk through a case before they actually walk into an operating room,” says Vikram M. Narayan, MD.
Latest:
Helen L. Bernie, DO, MPH, recaps the 2024 SMSNA Fall Scientific Meeting"I cannot wait to see what the SMSNA is going to have in store next year," says Helen L. Bernie, DO, MPH.
Latest:
Is a medical scribe right for your practice?“Regardless of the size of the practice, medical scribes are a valuable resource for health care providers, helping to streamline workflow and coordinate patient care,” writes Brian Hudson.
Latest:
Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidanceUrinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.
Latest:
Combo of cabozantinib and pembrolizumab shows promise in frontline urothelial carcinomaResults from the phase 2 PemCab trial showed that the first-line combination elicited promising antitumor activity with tolerable toxicity in patients with advanced urothelial carcinoma, including those who were cisplatin ineligible.
Latest:
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCCThe RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
